Open Access
HOW I DO IT
How I do it: percutaneous radiofrequency ablation (RFA)
Igor Sorokin1, Murthy Chamarthy2, Jeffrey A. Cadeddu1,2
1
Department of Urology, UT Southwestern Medical Center, Dallas, Texas, USA
2
Department of Radiology, UT Southwestern Medical Center, Dallas, Texas, USA
Address correspondence to Dr. Jeffrey A. Cadeddu,
Department of Urology, UT Southwestern Medical Center,
5323 Harry Hines Boulevard, Dallas, TX 75390 USA
Canadian Journal of Urology 2017, 24(1), 8679-8683.
Abstract
Percutaneous radiofrequency ablation has seen increased
utilization secondary to the rising incidence of renal cell
carcinoma. This has been shown to be an effective and
durable treatment especially in the elderly comorbid patient.
In this article, we describe our technique and factors related
to successful outcomes.
Keywords
percutaneous radiofrequency ablation, RFA, thermal ablation, renal mass, kidney cancer, renal cell carcinoma
Cite This Article
APA Style
Sorokin, I., Chamarthy, M., Cadeddu, J.A. (2017). How I do it: percutaneous radiofrequency ablation (RFA). Canadian Journal of Urology, 24(1), 8679–8683.
Vancouver Style
Sorokin I, Chamarthy M, Cadeddu JA. How I do it: percutaneous radiofrequency ablation (RFA). Can J Urology. 2017;24(1):8679–8683.
IEEE Style
I. Sorokin, M. Chamarthy, and J.A. Cadeddu, “How I do it: percutaneous radiofrequency ablation (RFA),” Can. J. Urology, vol. 24, no. 1, pp. 8679–8683, 2017.
Copyright © 2017 The Canadian Journal of Urology.